Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer
By: Hope S. Rugo, MD, FASCO
Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates
By: Joyce O’Shaughnessy, MD
Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 2)
By: Joyce O’Shaughnessy, MD
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)
By: Lajos Puzstai, MD, DPhil, FASCO
Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer
By: Mariana Chavez-McGregor, MD, MSc, FASCO
Project Optimus and Optimizing Dose and Schedule in Early Phase Clinical Trials
By: Jan H. Beumer, PhD, PharmD, PhD, DABT
Project Optimus and Optimizing Dose and Schedule in Early Phase Clinical Trials
By: Jan H. Beumer, PhD, PharmD, PhD, DABT
